Patents by Inventor Donald F. Weaver
Donald F. Weaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6930112Abstract: Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and epileptogenesis. Methods for preparing the compounds of the invention are also described.Type: GrantFiled: August 16, 2001Date of Patent: August 16, 2005Assignee: Queen's University at KingstonInventors: Donald F. Weaver, John R. Carran
-
Publication number: 20040248876Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: ApplicationFiled: May 2, 2003Publication date: December 9, 2004Applicant: Queen's University at Kingston and Neurochem, Inc.Inventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20040198832Abstract: Therapeutic compounds and methods for modulating amyloid aggregation in a subject, whatever its clinical setting, are described.Type: ApplicationFiled: August 11, 2003Publication date: October 7, 2004Applicants: Queen's University at Kingston, Neurochem (International) LimitedInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Heather Gordon
-
Publication number: 20030229144Abstract: Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and epileptogenesis. Methods for preparing the compounds of the invention are also described.Type: ApplicationFiled: August 16, 2001Publication date: December 11, 2003Applicant: Queen's University at KingstonInventors: Donald F. Weaver, Paul H. Milne, Christopher Y.K. Tan, John R. Carran
-
Publication number: 20030203923Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: ApplicationFiled: July 26, 2002Publication date: October 30, 2003Inventors: Gregory M. Ross, Egor L. Shamovsky, Sandra Marone, Donald F. Weaver, Richard J. Riopelle
-
Publication number: 20030194375Abstract: Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and/or epileptogenesis. Methods for preparing the compounds of the invention are also described.Type: ApplicationFiled: October 15, 2002Publication date: October 16, 2003Applicant: Queen's University at Kingston and Neurochem, Inc.Inventors: Donald F. Weaver, Christopher Y.K. Tan, Stephen T. Kim, Xianqi Kong, Lan Wei, John R. Carran
-
Publication number: 20030186901Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: ApplicationFiled: August 16, 2002Publication date: October 2, 2003Inventors: Gregory M. Ross, Igor L. Shamovsky, Sandra Marone, Donald F. Weaver, Richard J. Riopelle
-
Publication number: 20030153584Abstract: Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and/or epileptogenesis. Methods for preparing the compounds of the invention are also described.Type: ApplicationFiled: April 11, 2002Publication date: August 14, 2003Applicant: Queen's UniversityInventors: Donald F. Weaver, Buhendwa Musole Guillain, John R. Carran, Kathryn Jones
-
Publication number: 20030114441Abstract: Methods and compounds, such as &bgr;-heterocyclic-&bgr;-amino acids, useful for the inhibition of epileptogenesis are disclosed. Methods for preparing and using the &bgr;-heterocyclic-&bgr;-amino acids of the invention are also described.Type: ApplicationFiled: August 16, 2002Publication date: June 19, 2003Applicant: Queen's University at KingstonInventors: Donald F. Weaver, Allyson J. Campbell
-
Patent number: 6562836Abstract: Methods and compositions which are useful in the treatment of amyloidosis. In particular, methods and compositions are provided for inhibiting, preventing and treating amyloid deposition, e.g., in pancreatic islets, wherein the amyloidotic deposits are islet amyloid polypeptide (IAPP)-associated amyloid deposition or deposits. The methods of the invention involve administering to a subject a therapeutic compound which inhibits IAPP-associated amyloid deposits. Accordingly, the compositions and methods of the invention are useful for inhibiting IAPP-associated amyloidosis in disorders in which such amyloid deposition occurs, such as diabetes.Type: GrantFiled: May 23, 2000Date of Patent: May 13, 2003Assignee: Queen's University of KingstonInventors: Walter A. Szarek, Donald F. Weaver, Xianqi Kong, Ajay Gupta, David Migneault
-
Publication number: 20030077833Abstract: The present invention exploits the discovery that amounts of uracil and thymine metabolites, especially &bgr;-aminoisobutyric acid, in various bodily fluids, especially urine, are correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical and diagnostic protocols, including a novel high performance liquid chromatography system, for use in the invention are disclosed.Type: ApplicationFiled: August 16, 2002Publication date: April 24, 2003Applicant: Queen's University at KingstonInventors: Allyson J. Campbell, Donald F. Weaver, Angela P. Lyon, John R. Carran
-
Patent number: 6492380Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: GrantFiled: December 8, 1999Date of Patent: December 10, 2002Assignee: Queen's University at KingstonInventors: Gregory M. Ross, Igor L. Shamovsky, Sandra Marone, Donald F. Weaver, Richard J. Riopelle
-
Patent number: 6468990Abstract: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two of the following: (1) a first electronegative atom or functional group positioned to interact with Lys34 of nerve growth factor; (2) a second electronegative atom or functional group positioned to interact with Lys95 of nerve growth factor; (3) a third electronegative atom or functional group positioned to interact with Lys88 of nerve growth factor; (4) a fourth electronegative atom or functional group positioned to interact with Lys32 of nerve growth factor; and (5) a hydrophobic moiety which interacts with the hydrophobic region formed by Ile31, Phe101 and Phe86 of nerve growth factor.Type: GrantFiled: May 2, 2000Date of Patent: October 22, 2002Assignee: Queen's University at KingstonInventors: Gregory M. Ross, Igor L. Shamovsky, Sandra Marone, Donald F. Weaver, Richard J. Riopelle
-
Patent number: 6417159Abstract: The present invention provides methods and compositions for enhancing the effect of a neurotrophin on a cell expressing a neurotrophin receptor. The effect is preferably neurotrophin-mediated growth and/or survival, such as neurite growth. The invention employees amphipathic compounds having a hydrophobic membrane-associating face and a hydrophilic face opposed thereto, which preferably mimic the amphipathic domain of the common neurotrophin receptor p75 from amino acid residue 367 to residue 379. Such compounds have charged moieties, polar moieties or combinations that mimic the charged and polar group relationships of p75NTR367-379, and include but are not limited to peptide analogues thereof. The hydrophobic membrane-associating face can interact with a membrane-bound neurotrophin receptor, such as TrkA, and the opposing hydrophillic face can interact with a DNA binding protein, such as nuclear transcription factor NFkB.Type: GrantFiled: April 23, 1997Date of Patent: July 9, 2002Assignee: Queen's University at KingstonInventors: Richard J. Riopelle, Donald F. Weaver, Gregory M. Ross, Igor L. Shamovsky
-
Patent number: 6291247Abstract: Factors and methods for disrupting or inhibiting the association of protomers of a multimeric protein are described. Such inhibition reduces the biological disorders. Particularly, novel neurotrophin antagonists are described. Generally, the antagonist comprises amino acids from positions 68-58 and 108-110 of a neurotrophin, in which the amino acid from position 68 is covalently bound to the amino acid from position 108 and the amino acid from position 58 is covalently bound to the amino acid at position 110 to form a bicyclic structure, in another aspect of the invention transition metal ions are provided for selectively altering the geometry of the receptor binding domains of neurotrophins which allows functionality and activity of the neurotrophins to be selectively reduced. For example Zn2+ alters the conformation of NGF rendering it unable to bind to p75NTR or TrkA receptors or to activate signal transduction and biological outcomes normally induced by this protein.Type: GrantFiled: May 9, 1997Date of Patent: September 18, 2001Assignee: Queen's University at KingstonInventors: Richard J. Riopelle, Gregory M. Ross, Magdalena I. Dory, Donald F. Weaver, Igor L. Shamovsky
-
Patent number: 6029114Abstract: The present invention relates to computational methods for identifying the bioactive conformations of peptide domains, in particular the geometries of complexes of neurotrophins and neurotrophin receptors, and the geometries of neurotrophin receptors and ligands. The invention includes a method for identifying and theoretically modelling a receptor binding site for neurotrophins, such as NGF, BDNF, NT-3 and NT4/5, of the common neurotrophin receptor p75.sup.NTR. The principal residues of the p75.sup.NTR binding site are Asp.sup.47p, Lys.sup.56p, Asp.sup.75p, Asp.sup.76p, Asp.sup.88p and Glu.sup.88p of the second and third cysteine-rich domains. These residues interact with residues of variable loop regions I and V and other neighboring residues of each of the neurotrophins. The invention provides a method of designing a ligand for binding with common neurotrophin receptor p75.sup.Type: GrantFiled: July 31, 1997Date of Patent: February 22, 2000Assignee: Queen's University at KingstonInventors: Igor L. Shamovsky, Gregory M. Ross, Richard J. Riopelle, Donald F. Weaver